Therefore, SHP‐1 agonists may be a new therapeutic approach in these diseases to antagonize the clonal advantage of JAK2V617F mutated cells and avoid the development of secondary MPN in people with CHIP. Here, STUB1 is linked to myeloproliferative disorder.